Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management

Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
 
RESEARCH TRIANGLE PARK, N.C., July 8 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics Holdings Corp. (Nasdaq:TLCR - News) today announced that Lafmin Morgan has joined the Global Commercial Operations team as vice president, U.S. Product Management.  In this role, Morgan will be responsible for product management and marketing of the company's full product portfolio in the U.S.

"Lafmin brings significant experience and leadership to Talecris and will strengthen our capabilities as we pursue the continued growth of Talecris' U.S. business," said John Perkins, executive vice president, Global Commercial Operations.

Morgan joins Talecris from GlaxoSmithKline (GSK), where he served for more than twenty years in finance, sales, commercial strategy and marketing roles across multiple therapeutic areas. His most recent role at GSK was vice president, Commercial Model Innovations, in which he led GSK's effort to build a new sales and marketing model for the company's entire U.S. business.

Prior to that, Morgan served at GSK as vice president of Sales, a position in which he managed a 2000-person sales force and served as chair of the U.S. Sales Leadership Team. He also served as vice president of Respiratory Marketing, where he implemented a marketing strategy that grew the $5 billion respiratory portfolio by 13 percent in just over one year. 

Morgan holds a Bachelor of Science in Business Administration and a Master of Business Administration from the University of North Carolina at Chapel Hill.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: www.talecris.com

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.